CNS Pharmaceuticals, Inc.
CNSP
$4.59
-$0.30-6.14%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.43M | 2.82M | 1.06M | 1.24M | 1.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.98M | 5.99M | 3.25M | 2.41M | 4.34M |
| Operating Income | -4.98M | -5.99M | -3.25M | -2.41M | -4.34M |
| Income Before Tax | -4.94M | -5.96M | -3.22M | -2.38M | -4.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.94M | -5.96M | -3.22M | -2.38M | -4.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.94M | -5.96M | -3.22M | -2.38M | -4.30M |
| EBIT | -4.98M | -5.99M | -3.25M | -2.41M | -4.34M |
| EBITDA | -4.97M | -5.99M | -3.25M | -2.41M | -4.34M |
| EPS Basic | -7.30 | -9.70 | -5.76 | -6.42 | -18.93 |
| Normalized Basic EPS | -4.56 | -6.06 | -3.60 | -4.01 | -11.83 |
| EPS Diluted | -7.30 | -9.70 | -5.76 | -6.42 | -18.93 |
| Normalized Diluted EPS | -4.56 | -6.06 | -3.60 | -4.01 | -11.83 |
| Average Basic Shares Outstanding | 676.20K | 613.80K | 558.90K | 370.10K | 227.20K |
| Average Diluted Shares Outstanding | 676.20K | 613.80K | 558.90K | 370.10K | 227.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |